ArticleAnnals of clinical and translational neurology2026
Long-Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy-A 10-Year Follow Up Study.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAutoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long-term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long-term treatment response, residual autonomic dysfunction, and relapse patterns in patients with seropositive AAG.
methodsPatients with seropositive AAG undergoing longitudinal follow-up with repeated quantitative autonomic assessments before and after immunotherapy were included. Residual autonomic impairment was assessed using cardiovascular, pupillary, and urinary autonomic biomarkers, need for anti-hypotensive medications or catheterisation, and patient-reported symptoms measured by the COMPASS-31 questionnaire.
resultsOf 18 patients with seropositive AAG, 16 had longitudinal quantitative autonomic testing, antibody titres, COMPASS-31 scores, and documented medication and catheter use before and after immunotherapy. At baseline, all 16 had widespread autonomic failure. All received plasma exchange, 10 received intravenous immunoglobulins, and 11 were treated with oral prednisolone followed by steroid-sparing agents. Treatment was associated with significant improvements in cardiovascular autonomic markers, antibody titres, and pupillary light responses, with non-significant improvements in COMPASS-31 scores. Four patients discontinued catheterisation. Two patients were refractory to plasma exchange and intravenous immunoglobulins but responded to prednisolone. Two patients relapsed while receiving steroid-sparing immunotherapy. High antibody titres correlated with the severity of cardiovascular and urinary dysfunction at disease onset, but not during follow-up.
interpretationProlonged stepwise immunosuppression in seropositive AAG is associated with sustained objective autonomic improvement, although residual impairment and relapse remain common. These findings support individualised, biomarker-guided immunotherapy and highlight the need for ongoing supportive management of autonomic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.